Asociación de pravastatina y fenofibrato (Pravafenix®). Estudios de seguridad

Abstract

Although LDL cholesterol is the primary treatment objective for reducing cardiovascular risk, the increase in triglyceride levels and the reduction of HDL cholesterol levels constitute the so-called residual cardiovascular risk. Treatment with statins combined with fibrates is an actual possibility for the treatment of overall cardiovascular risk. However, this combination is often associated with adverse eff ects, especially muscular and hepatic.Due to its pharmacological characteristics, the combination of pravastatin and fenofibrate can be eff ective and safe, with few adverse eff ects. In this review, we analyze the available safety studies and conclude that Pravafenix® (the combination of 40-mg pravastatin and 160-mg fenofibrate) achieves complementary benefits on the overall atherogenic lipid profile, is well tolerated and has few adverse eff ects, which is similar to the monotherapy of each of its components. It remains to be seen whether this combination confers additional long-term benefits for patients treated with statins.